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Introduction: The aim of this study was to examine the effects of 
KRAS mutant subtypes on the outcome of patients with resected lung 
adenocarcinoma (AC).
Methods: Using clinical and sequencing data, we identified 179 
patients with resected lung AC for whom KRAS mutational status 
was determined. A multivariate Cox model was used to identify fac-
tors associated with disease-free survival (DFS) and overall survival 
(OS). Publicly available mutation and gene-expression data from 
lung cancer cell lines and lung AC were used to assess whether dis-
tinct KRAS mutant variants have a different profile.
Results: Patients with KRAS mutation had a significantly shorter 
DFS compared with those with KRAS wild-type (p = 0.009). Patients 
with KRAS-G12C mutant tumors had significantly shorter DFS com-
pared with other KRAS mutants and KRAS wild-type tumors (p < 
0.001). In the multivariate Cox model, KRAS-G12C remained as 
an independent prognostic marker for DFS (Hazard ratio = 2.46, 
95% confidence interval 1.51–4.00, p < 0.001) and for OS (Hazard 
ratio = 2.35, 95% confidence interval 1.35–4.10, p = 0.003). No genes 
were statistically significant when comparing the mutational or tran-
scriptional profile of lung cancer cell lines and lung AC harboring 
KRAS-G12C with other KRAS mutant subtypes. Gene set enrichment 
analysis revealed that KRAS-G12C mutants overexpressed epithelial 
to mesenchymal transition genes and expressed lower levels of genes 
predicting KRAS dependency.
Conclusions: KRAS-G12C mutation is associated with worse DFS 
and OS in resected lung AC. Gene-expression profiles in lung cancer 
cell lines and surgically resected lung AC revealed that KRAS-G12C 
mutants had an epithelial to mesenchymal transition and a KRAS-
independent phenotype.
Key Words: KRAS mutation, Lung adenocarcinoma, Prognostic 
markers.
(J Thorac Oncol. 2014;9: 1513–1522)
Mutation in the KRAS gene is one of the most frequently detected activating mutations in lung adenocarcinomas 
(AC).1 KRAS mutations in lung AC usually arise at codon 12, 
occasionally at codon 13, and rarely at codon 61. KRAS muta-
tions are predominantly found in smokers and these smoking-
related KRAS mutations generally are G→T transversions, in 
contrast to the G→A transitions found in colorectal cancer and 
in lung AC patients who never smoked.2–5 This distinct muta-
tional profile suggests the convergence of diverse carcinogens 
in the induction of KRAS mutation that seems to be an early 
event of lung tumorigenesis, being detectable in the smoking-
related lung AC precursor, atypical alveolar hyperplasia.6,7
KRAS belongs to the RAS human gene family that acts 
as signal switch molecule cycling between an active guano-
sine triphosphate (GTP)-bound state and an inactive guano-
sine diphosphate (GDP) state. GDP/GTP cycling is positively 
regulated by guanine nucleotide exchanging factor and nega-
tively regulated by GTPase-activating proteins (e.g., NF1). 
Oncogenic Ras proteins have defective intrinsic GTPase func-
tion and are resistant to GTPase-activating proteins, leading 
to accumulation of Ras in its active GTP-bound state, which 
causes constitutive activation of Ras signaling. GTP-bound 
active Ras recruits and activates downstream pathways such 
as RAF−MEK−ERK-promoting cell proliferation or PI3K/
AKT-inducing inhibition of apoptosis.8 At least nine specific 
KRAS mutations have been identified in lung cancer, based on 
the amino acid substitution,9 and these distinct KRAS mutants 
have differential binding affinity for downstream effector 
molecules. For example, mutant KRAS-G12D demonstrated 
higher affinity for PI3K, whereas mutant KRAS-G12C had 
higher affinity for RalGDS.10 In addition, different amino acid 
substitutions might activate different signaling pathways and 
indeed, give rise to varying responses rates to chemotherapy 
and some targeted therapies in lung cancer cell lines and 
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advanced lung ACs.10,11 Recent studies have added a new level 
of complexity because non–small-cell lung cancer (NSCLC) 
cell lines harboring KRAS-activating mutations can be strati-
fied into KRAS dependent and KRAS independent based on 
the effect of the KRAS ablation on cell proliferation or induc-
tion of apoptosis.12,13
The prognostic value of KRAS mutations remains con-
troversial in lung cancer. Several studies reported that KRAS 
mutations are a marker of poor prognosis in NSCLC.14 In a 
recent study, involving 1500 resected NSCLC, KRAS muta-
tion was not prognostic for survival and did not predict ben-
efit from adjuvant chemotherapy.15 In advanced NSCLC, the 
various amino acid substitutions predicted different clinical 
outcomes.10 For example, KRAS-G12C and KRAS-G12V pre-
dicted worse progression-free survival (PFS), whereas other 
KRAS mutants predicted better PFS. We hypothesized that 
specific amino acid KRAS substitutions are associated with 
differing outcomes in patients with surgically resected lung 
ACs.
In this study, we determined the prognostic value of spe-
cific amino acid substitutions among 179 resected lung ACs 
using our data set and comparing and contrasting our results 
with data from other studies. In addition, we used publicly 
available data bases to elucidate whether the various codon 
mutants had different mutational profiles and varying degree 
of RAS dependency.
PATIENTS AND METHODS
Human Samples
In this retrospective study, we examined 179 primary 
lung ACs obtained from patients undergoing primary tho-
racic resection for lung cancer at the University of Michigan 
Health System, Ann Arbor, Michigan, during 1991–2007 
for whom KRAS mutation status was known. This cohort 
encompassed an initial set of tumors from a previous study 
wherein 86 lung ACs were mRNA profiled16 and a second 
set of 93 tumors subsequently used for validating specific 
genes. None of the patients included in this study received 
preoperative radiation or chemotherapy. Tissue specimens 
were banked with informed consent after approval from 
University of Michigan Institutional Review Board and 
Ethics Committee and were frozen in liquid nitrogen and 
stored at −80°C. Regions containing a minimum of 70% 
tumor cellularity were utilized for DNA and RNA isolation. 
Clinical data were retrospectively collected from the medical 
records and all cases were staged according to the revised 
7th TNM classification criteria.17
DNA Extraction and Sequencing Techniques
Genomic DNA was isolated using the phenol-chloro-
form method and dissolved in TE buffer. KRAS mutations 
were determined using polymerase chain reaction (PCR) and 
Sanger sequencing protocol for all samples. PCR was per-
formed using 5 ng genomic DNA with 38 cycles according 
to the following conditions: 94°C for 30 seconds, 56°C for 30 
seconds, and 68°C for 45 seconds. PCR products were subse-
quently purified using ExoSAP-IT PCR purification product 
(USB/Affymetrix), according to the manufacturer’s instruc-
tions. PCR products were then sequenced using the M13 for-
ward primer at the University of Michigan Sequencing Core. 
Sequence data were analyzed for the presence of canonical 
activating KRAS mutations at codons 12, 13, and 61. Primers 
used for the PCR reactions were KRAS exon 2 forward: 
TCTTAAGCGTCGATGGAGGAG, KRAS exon 2-M13 reverse: 
GTAAAACGACGGCCAGTTTGAAACCCAAGGTA 
CATTTCAG, KRAS exon 3 forward: CGTCATCTTTGG 
AGCAGGAAC, KRAS exon 3-M13 antisense: GTAAAACGA 
CGGCCAGTATGCATGGCATTAGCAAAGAC.
Gene Expression and Copy Number 
Data from Lung Cancer Cell Lines 
and Patients with Lung AC
Publicly available Affymetrix U133 Plus 2.0 micro-
array data from lung cell lines were downloaded from the 
National Cancer for Biotechnology Information website 
(GSE36133).18 Cell line mutational status was obtained from 
the Sanger Institute Catalogue of Somatic Mutations In Cancer 
(COSMIC) Web site9 and is shown in Supplementary Table 1 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A673). Publicly available Affymetrix U133A 2.0 microarray 
and mutation data from 102 lung AC19 were downloaded from 
http://cbio.mskcc.org/public/lung_array_data/, and the raw 
expression data were normalized using the Robust Multichip 
Average (RMA) normalization method20 and then was log2-
transformed and median centered. Pathways gene lists were 
developed as previously reported21; KRAS dependency genes 
and epithelial to mesenchymal (EMT) related genes were 
obtained from primary literature sources.12,22 The pathway 
expression data was computed for each tumor as the arithmetic 
mean of all genes included in each pathway gene list. Mutation 
information from 623 genes and KRAS gene copy number was 
available from a previous study in lung AC1 (http://genome.
wustl.edu/pub/supplemental/ tsp_nature_2008/). Clinical 
outcome was available from 67 patients with KRAS mutant 
tumors included in the TCGA–Lung AC study, and these data 
were downloaded from the TCGA portal (https://tcga-data.
nci.nih.gov). Supervised clustering based on genes associated 
with KRAS dependency12,13 and EMT analysis was performed 
using Cluster v3.023 and the heat-map plotted using Treeview 
software.24
Statistical Analysis
Chi-square, Fisher’s exact tests, or Student’s t tests were 
used to identify statistically significant differences between 
different clinical variables and the type of KRAS mutations. 
For in vitro studies, the significance of difference between the 
experimental groups was calculated by the Student’s t test. 
The outcome variables for survival analysis were disease-free 
survival (DFS) and overall survival (OS). DFS was measured 
from the date of surgery to the time of recurrence, death, or 
censoring at 5 years. OS was measured from date of surgery 
to the time of death or censoring at 5 years. Survival curves 
were constructed using the method of Kaplan–Meier, and sur-
vival differences were assessed using the log-rank test. The 
univariate and multivariate Cox proportional hazards model 
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including the covariates of age, gender, disease stage, smok-
ing history, adjuvant treatment, and differentiation were used 
to assess the prognostic value of KRAS mutations on DFS and 
OS. With a median follow-up time of 7.9 years (±3.6), 102 
patients (57%) have died among 179 patients. Statistical sig-
nificance was defined as a p-value less than 0.05.
RESULTS
Frequency of KRAS Mutation and 
Correlation with Clinical Characteristics
In 179 surgically resected lung AC, KRAS mutations in 
codon 12, 13, and 61 were found in 47.5% (85 of 179; 95% 
confidence intervals [CIs] 40–55). Most KRAS mutations 
(90.6%, 95% CI 84.2–96.9) were located in codon 12, whereas 
only seven (8.2%, 95% CI 2.3–14.2) were in codon 13 and one 
(1.2%, 95% CI −1.2 to 3.5) in codon 61. Transversion muta-
tions (74.1%; 95% CI 64.6–83.6) were more common than 
transition mutations (25.9%; 95% CI 16.4–35.4), as previously 
reported.4 According to the amino acid substitution, the most 
frequent mutation was G12C (41.2%) as shown in Table 1.
Correlation of KRAS mutation status with clinical char-
acteristics is shown in Table 2. KRAS mutations were signifi-
cantly associated with higher tumor grade (p = 0.023) and a 
lower frequency of Asians and never smokers (p = 0.044 and 
0.003, respectively). Interestingly, the packs/year consumed 
by patients with KRAS mutant tumors was significantly higher 
(mean and standard error, 46.2 ± 3.3) compared with those 
with KRAS wild-type (37.2 ± 3.3; p = 0.013). Furthermore, the 
median pack-years consumed was higher among patients har-
boring a G→T KRAS mutation as compared with other nucle-
otide substitutions (G→A and G→C) or KRAS wild-type 
(Supplementary Fig. 1, Supplemental Digital Content 2, http://
links.lww.com/JTO/A674). Patients with tumors harboring 
KRAS mutations were not significantly different from patients 
with KRAS wild-type tumors in terms of age, gender, stage, 
type of lung resection, or adjuvant treatment. We also exam-
ined the correlation between the clinicopathological variables 
and the type of amino acid substitution (Supplementary Table 
2, Supplemental Digital Content 1, http://links.lww.com/
JTO/A673) and found that the proportion of heavy smokers 
(≥35 packs/year) was higher among patients with G12C and 
G12A mutations (p = 0.045).
KRAS-G12C Mutation Is Associated with Poor 
Outcome in Resected Lung AC Tumors
We determined the prognostic value of KRAS mutation 
in this cohort of surgically resected lung ACs and found a sig-
nificant association between KRAS mutation and recurrence or 
death (65%) as compared with KRAS wild-type (45%, Fisher’s 
exact test p = 0.010). Strikingly, patients whose tumors har-
bored KRAS-G12C mutations had a significantly higher fre-
quency of recurrence or death (82.9%) as compared with 
non-G12C mutations (52%, Fisher’s exact test p = 0.005).
Patients with KRAS mutation had a significantly shorter 
median DFS (28.5 months, 95% CI 16.8–40.2) as compared 
with those with KRAS wild-type (median not reached, Log-
rank p = 0.006, Fig. 1A). The estimated DFS rate at 24 months 
for KRAS mutant and wild-type was 55.3% ± 5.4 and 73.4% ± 
4.6, respectively. Remarkably, when the survival analysis was 
carried out only in stage I patients (n = 121), we observed 
that patients whose tumors harbored KRAS mutations had a 
significantly shorter DFS (Fig. 1B). Concordantly, patients 
whose tumors harbored KRAS mutations had a significantly 
lower OS rate at 24 months (72.9% ± 4.8) as compared with 
those with KRAS wild-type (79.6% ± 4.2, Log-rank p = 0.041, 
Fig. 1C). The univariate analysis for DFS and OS includ-
ing clinical and molecular variables is shown in Table 3. 
Statistically significant clinical covariates in the univariate 
Cox model (Supplementary Table 3, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A673) were used in the 
DFS multivariate analysis examining the prognostic value of 
KRAS mutations. KRAS mutation was independently asso-
ciated with worse DFS (hazard ratio [HR] = 1.65, 95% CI 
1.19–2.74, p = 0.005, Supplementary Table 4, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A673) after 
adjusting for gender and stage.
In the univariate analysis, we found that KRAS-G12C 
mutation was significantly associated with worse DFS 
(HR = 2.91, 95% CI 1.80–4.72, p < 0.001) as compared with 
other KRAS codon variants or wild-type (Table 3, Fig. 1D). 
Patients harboring KRAS-G12C mutations had significantly 
worse DFS rate at 2 years (42.9% ± 8.4) as compared with 
other KRAS mutants (G12A, 75% ± 15.3; G12V, 78.6% 
± 11.0; G12D, 53.3% ± 12.9) and wild-type (73.4% ± 4.6; 
log-rank test p < 0.001; Supplementary Fig. 2, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A674). When the 
survival analysis was restricted to stage I patients (n = 121), 
we observed that patients whose tumors harbored KRAS muta-
tions had a significantly shorter OS (Fig. 1E). Concordantly, 
patients with KRAS-G12C mutations had significantly worse 
OS rate at 2 years (60% ± 8.3), whereas KRAS–non-G12C 
showed similar OS rates (G12A, 87.5% ± 11.7; G12V, 92.9% 
± 6.9; G12D, 86.7% ± 8.8) to patients with KRAS wild-type 
(79.6% ± 4.2; log-rank test p = 0.004; Fig. 1F).
In the multivariate Cox model (after adjusting for gender 
and stage), KRAS-G12C remained as an independent prognos-
tic marker for DFS (HR = 2.45, 95% CI 1.50–3.99, p < 0.001, 
Supplementary Table 4, Supplemental Digital Content 1, 
TABLE 1.  Frequency of KRAS Mutation according to Amino 
Acid Change
KRAS Mutation Type n %
95% Confidence 
Intervals
G12C (GGT→ TGT) 35 41.2 30.5–51.8
G12D (GGT→ GAT) 15 17.6 9.4–25.9
G12V (GGT → GTT) 14 16.5 8.4–24.5
G12A (GGT → GCT) 8 9.4 3.1–15.7
G13D (GGC → GAC) 5 5.9 0.8–10.9
G12S (GGT →AGT) 3 3.5 −0.5 to 7.5
G12R (GGT →CGT) 2 2.3 −0.9 to 5.6
G13C (GGC→TGC) 1 1.2 −1.2 to 3.5
G13V (GGC → GTC) 1 1.2 −1.2 to 3.5
Q61H (CAA → CAC) 1 1.2 −1.2 to 3.5
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 http://links.lww.com/JTO/A673) and for OS (HR = 2.36, 95% 
CI 1.35–4.12, p = 0.002). When tobacco history was included in 
the multivariate analysis, KRAS-G12C remained independently 
associated with worse DFS (HR = 2.47, 95% CI 1.48–4.11, 
p = 0.001) and worse OS (HR = 2.04, 95% CI 1.15–3.62, 
p = 0.015) as well.
Available survival data and KRAS mutational status 
from TCGA-LUAC cases were analyzed to assess the prog-
nostic value of KRAS-G12C in lung AC. Although the data 
available was limited to a small subset of patients and the 
median follow-up was less than 5 years, we observed that 
patients harboring KRAS-G12C mutations had significantly 
worse OS as compared with other KRAS mutants indepen-
dently of stage and adjuvant treatment (Supplementary 
Fig. 3, Supplemental Digital Content 2, http://links.lww.
com/JTO/A674).
NSCLC Cell Lines Harboring KRAS-G12C 
Cells Present an EMT Phenotype
We analyzed the mutational status and expression pro-
file of KRAS-G12C and non-G12C NSCLC cells. On the basis 
of the COSMIC database,9 no statistically significant differ-
ences in the mutational status of other known driver genes 
(TP53, STK11, PTEN, PIK3CA, CDKN2A, RB1, or NF1) were 
observed among KRAS-G12C and non-G12C cells (Fig. 2A).
Next, we assessed whether KRAS dependency is associ-
ated with specific codon variants based on the data available 
from previous studies in different cancer cells.12,25 Cell lines 
harboring KRAS-G12C mutations or cells containing codon 
13 and 61 mutations were more likely to be KRAS indepen-
dent (73% and 77%) as compared with KRAS-G12A, D, V, or 
S mutations (45%, χ2 p = 0.08, Fig. 2B). Indeed, most NSCLC 
KRAS-G12C cell lines have been experimentally characterized 
TABLE 2.  Correlation between KRAS Mutation Status and Clinicopathological Characteristics
All Patients (n = 179)
n (%)
KRAS Mutant (n = 85)
n (%)
KRAS Wild-Type (n = 94)
n (%) p
Age (average, SD)
(range)
65.8 ± 9.8
(40–88)
64.9 ± 9.4
(40–85)
66.7 ± 10.2
(42–88)
0.165a
Gender
  Male 75 (41.9) 32 (37.6) 43 (45.7) 0.292b
  Female 104 (58.1) 53 (62.4) 51 (54.3)
Race
  Caucasian 149 (83.2) 77 (90.6) 72 (76.6) 0.044c
  African American 9 (5.0) 4 (4.7) 5 (5.3)
  Asian 8 (4.5) 1 (1.2) 7 (7.4)
  Unknown 13 (7.3) 3 (3.5) 10 (10.6)
Stage
  I 121 (67.6) 55 (64.7) 66 (70.2) 0.343c
  II 23 (12.8) 9 (10.6) 14 (14.9)
  III 29 (16.2) 18 (21.2) 11 (11.7)
  IV 6 (3.4) 3 (3.5) 3 (3.2)
Type of surgery
  Lobectomy 169 (94.4) 79 (92.9) 90 (95.7) 0.502c
  Pneumonectomy or 
bilobectomy
9 (5.0) 5 (5.9) 4 (4.3)
  Segmentectomy 1 (0.6) 1 (1.2) 0 (0)
Adjuvant treatment
  No 132 (73.7) 59 (69.4) 73 (77.7) 0.382c
  Yes 41 (22.7) 22 (25.9) 19 (20.2)
  Unknown 6 (3.3) 4 (4.7) 2 (2.1)
Differentiation
  Well 42 (23.5) 21 (24.7) 21 (22.3) 0.023c
  Moderate 83 (46.4) 31 (36.5) 50 (55.3)
  Poor 54 (30.2) 33 (38.8) 21 (22.3)
Smoking
  Smoker 154 (86.0) 79 (92.9) 75 (79.8) 0.003c
  Nonsmoker 23 (12.8) 4 (4.7) 19 (20.2)
  Unknown 2 (1.2) 2 (2.4) 0 (0)
aStudent’s t test.
bFisher’s exact test.
cPearson χ2 test.
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as KRAS independent in previous studies12,13 (Supplementary 
Table 1, Supplemental Digital Content 1, http://links.lww.
com/JTO/A673). Using NSCLC cell lines microarray data,18 
no genes were differentially expressed among KRAS-G12C 
and non-G12C at FDR ≤ 0.1, likely due to a lack of statisti-
cal power in the analysis. However, most KRAS-G12C cells 
had an EMT phenotype, which has been associated with being 
KRAS independent (Fig. 2C). Supervised clustering based on 
genes positively correlated with KRAS dependency and EMT 
genes revealed that most KRAS-G12C cells cluster with non-
G12C cells that have been classified as KRAS independent.
KRAS-G12C Is Associated with EMT and 
KRAS Independence in Primary Lung AC
We used DNA sequencing data from a previous study1 
to assess the mutational profile of KRAS-G12C versus non-
G12C lung AC. In this study, the mutational status of 623 rel-
evant genes in cancer was determined in 188 lung AC. We 
focused the analysis on KRAS mutant tumors and we found 
that KRAS-G12C had a trend toward a higher number of 
mutations (n = 23, mean and SE 8.7 ± 2.2) as compared with 
the codon variants that are also frequent in lung AC such as 
KRAS-G12A, G12D, and G12V (n = 21, 4.3 ± 0.7, Student’s 
t test p = 0.07, Fig. 3A). In the small subset of tumors har-
boring less frequent mutations such as KRAS-G12F, G12R, 
and G12S, the average mutation number was remarkably high 
(n = 10, 11.5 ± 2.8), whereas the tumors with codon 13 and 61 
mutations have a similar number of mutations as KRAS-G12C 
(n = 10, 7.6 ± 1.3). Congruently with cell lines, we did not 
observe statistically significant differences in the co-occur-
rence of TP53 and STK11 mutations among KRAS-G12C and 
non-G12C lung AC.
Next, we assessed KRAS gene copy number according to 
the type of codon variant using SNP 250K data from the 59 
lung AC harboring KRAS mutations. We found that 19% of 
KRAS–non-G12C tumors (n = 36) harbored high KRAS copy 
number (≥2.5) as compared with 0% of KRAS-G12C tumors 
(n = 23, Fisher’s exact test p = 0.036, Fig. 3B). We compared 
the expression profile of KRAS-G12C and non-G12C mutants 
using Chitale’s cohort19 of 102 lung AC, and no significant 
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FIGURE 1. A and B, Kaplan–Meier plots of DFS according to KRAS status (mutant versus wild-type) in lung AC patients of all 
stages (n = 179) and stage I (n =121). C, Kaplan–Meier plot of OS according to KRAS status (mutant versus wild-type) in lung 
AC patients of all stages (n = 179). D and E, Kaplan–Meier plots of DFS for KRAS wild-type, KRAS-G12C and KRAS–non-G12C in 
lung AC patients of all stages (n = 179) and stage I (n = 121). F, Kaplan–Meier plot of OS for KRAS wild-type, KRAS-G12C, and 
KRAS–non-G12C in lung AC patients of all stages (n = 179). DFS, disease-free survival; AC, adenocarcinoma; OS, overall survival.
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genes were differentially expressed at FDR ≤ 0.1. Tumors har-
boring specific KRAS codon variants appeared intermixed with 
other codon variants and KRAS wild-type tumors by performing 
an unsupervised clustering based on the 10,000 most variable 
probes (data not shown). Gene set enrichment analysis showed 
that KRAS-G12C lung AC expressed significantly higher levels 
of EMT-related genes and angiogenesis-related genes as com-
pared with KRAS–non-G12C tumors (Student’s t test p = 0.028 
and 0.020, Fig. 3C). In addition, KRAS-G12C tumors had sig-
nificantly lower mean expression of validated genes for KRAS 
dependency (SYK, ITGB6, MST1R, and LYN) as compared with 
KRAS–non-G12C (Student’s t test p = 0.048). These results 
suggested that KRAS-G12C mutant tumors might be associated 
with a KRAS-independent phenotype, but further studies are 
warranted to test this hypothesis.
DISCUSSION
We tested the hypothesis that specific KRAS amino acid 
substitutions will predict clinical natural history in surgically 
resected lung AC. Using our repository of 179 well-character-
ized lung ACs, we found KRAS mutation in 47.5% of tumors. 
We anticipated this high proportion because only patients with 
known KRAS status were included in this retrospective study. 
As previously reported in NSCLC, most KRAS mutations in 
our data set were found at codon 12, which is one of the most 
sensitive areas in the human genome for mutagenic damage.26 
Although codon 12 mutations have been described in both 
smoking-associated lung cancers and nonsmoking-associ-
ated colon and pancreatic cancers, cigarette smoke typically 
induces transversion mutations, whereas noncigarette smoke 
associated mutations are generally transition mutations.3 In 
addition, the type of amino acid substitution varies notice-
ably between lung cancer and gastrointestinal tumors, as it has 
been recently reported.5
We found that KRAS-G12C (41.2%) is the most fre-
quent mutation in resected lung ACs, followed by G12D 
(17.6%) and G12V (16.5%). On the basis of available data in 
the COSMIC database (Catalogue of Somatic Mutations in 
TABLE 3.  Univariate Analysis of Disease-Free Survival and Overall Survival according to Clinical and Molecular Variables
Univariate Analysis 
(172 Patients)a
Disease-Free Survival Overall Survival
HR 95% CI p HR 95% CI p
Age, continuous 1.00 0.98–1.02 0.969 1.01 0.99–1.04 0.266
Sex
  Female 1.00 — 1.00 —
  Male 1.33 0.88–1.99 0.175 1.56 0.97–2.52 0.065
Stage, continuous 2.10 1.73–2.55 <0.001 1.99 1.60–2.49 <0.001
Smoking status
  Nonsmoker 1.00 — 1.00 —
  Smoker 1.55 0.78–3.09 0.208 2.88 1.05–7.92 0.040
Adjuvant therapy
  No 1.00 — 1.00 —
  Yes 2.69 1.74–4.18 <0.001 2.32 1.41–3.83 0.001
Differentiation
  Well 1.00 — 1.00 —
  Moderate 1.21 0.69–2.12 0.507 1.34 0.67–2.66 0.406
  Poor 1.69 0.94–3.04 0.077 2.04 1.01–4.14 0.047
KRAS mutation
  Wild-type 1.00 — 1.00 —
  Mutant 1.89 1.25–2.85 0.002 1.75 1.08–2.83 0.023
Type of KRAS mutation
  Wild-type 1.00 — 1.00 —
  G12D 1.64 0.73–3.66 0.228 0.99 0.37–2.99 0.921
  G12V 1.37 0.61–3.05 0.446 1.03 0.36–2.94 0.939
  G12A 0.81 0.25–2.61 0.719 0.75 0.18–4.22 0.639
  Other 1.45 0.65–3.23 0.367 1.75 0.73–4.22 0.212
  G12C 2.91 1.80–4.72 <0.001 2.71 1.57–4.69 <0.001
KRAS mutation groups
  Wild-type 1.00 — 1.00 —
  Non-G12C 1.34 0.81–2.22 0.386 1.16 0.63–2.14 0.627
  G12C 2.91 1.79–4.71 <0.001 2.71 1.56–4.69 <0.001
aPatients with missing smoking or adjuvant data were not included in the analysis.
HR, hazard ratio; CI, confidence interval.
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Cancer),9 KRAS-G12C mutation was also the most common 
type of KRAS amino acid substitution in lung cancer cell lines 
(34%) and primary tumors (41%). Similarly, two recent stud-
ies including 605 and 988 lung AC patients reported an even 
higher prevalence of KRAS-G12C mutations (47%–48%) 
compared with what we observed.15,27 Strikingly, in our study, 
patients harboring KRAS-G12C mutations were more likely to 
have been heavy smokers and G→T transversions were cor-
related with higher pack-years.
Several studies and one meta-analysis have reported 
that KRAS mutation has a negative impact on patient out-
comes.14,28,29 In our study, we observed that patients with 
tumors harboring a KRAS mutation had worse survival as 
compared with patients with KRAS wild-type tumors. In addi-
tion, our data demonstrated that KRAS-G12C mutations were 
associated with poor outcome after lung AC resection inde-
pendent of gender, tumor stage, or smoking history. These 
data suggest that the prognostic significance of KRAS-G12C 
was not merely reflective of a confounding effect of tobacco 
history or stage on survival. Analogous results have been 
reported in advanced NSCLC patients enrolled in a bio-
marker-driven clinical trial, where KRAS-G12C patients had a 
significantly shorter median PFS than those with other KRAS 
mutations (p = 0.046).10 Similarly, the KRAS in Colorectal 
Cancer Collaborative Group (RASCAL-II) showed that G→T 
mutations and particularly G12V mutations were associated 
with worse failure-free survival and OS in colorectal cancer 
patients.30
However, in two recent large studies examining 605 
and 988 lung ACs, neither KRAS mutation status nor the type 
of substitution was prognostic for survival.15,27 In these two 
studies, formalin-fixed paraffin-embedded tissue samples 
were assessed for KRAS status using different techniques 
(Supplementary Table 5, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A673). In the study by Villaruz 
et al., microdissection was used for tumor enrichment and 
areas containing more than 70% tumor cells were selected. 
In this study, 45% of patients had stage I lung ACs and 23% 
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FIGURE 2. A, Bar plot showing the frequency of TP53, STK11, PTEN, and PIK3CA mutation according to specific codon 
variants in 16 KRAS mutant NSCLC cell lines. B, Bar plot showing the frequency of KRAS independence according to specific 
KRAS mutations in 53 mutant cancer cell lines. C, Heat-map showing supervised clustering based on genes associated with 
KRAS dependency (SYK, ITGB6, RBM35B, LYN, MST1R, LCK, ERBB3, PAK1, and MET) and EMT genes for a panel of KRAS mutant 
NSCLC cell lines. The central panel displays the presence (black) or absence (white) of activating mutations in TP53, STK11, 
and PIK3CA genes and whether these cells were classified as KRAS-dependent (green) or independent cells (red). Most KRAS-
G12C mutant cells clustered together with other KRAS-independent cells and displayed an EMT phenotype. NSCLC, non–
small-cell lung cancer.
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received some form of adjuvant therapy. The study reported 
by Shepherd et al. included samples from four different stud-
ies (IALT, ANITA, JBR.10, and CALGB). Samples collected 
within the first two studies were macrodissected for areas 
containing more than 30% tumor cells; there is no mention 
whether tumor enrichment was performed for the JBR.10 and 
CALGB studies. In this study, 49% of patients had stage I lung 
cancer and approximately 50% received adjuvant therapy. In 
contrast, our study included a higher proportion of stage I lung 
cancer (68%) with a longer median follow-up (96 months) 
and only 23% of patients received adjuvant chemotherapy. In 
our study, KRAS status was uniformly determined by Sanger 
sequencing using frozen tumors and only regions containing 
more than 70% tumor cellularity were used for nucleic acid 
isolation. We did not group KRAS-G12C patients with G12V 
because their outcomes were distinct in the survival analysis 
and we were interested in determining the impact on survival 
of individual KRAS amino acid substitutions. We consider that 
intrinsic lung AC heterogeneity and striking methodological 
differences among these three studies (differences in study 
population, varying criteria for tumor enrichment, or diverse 
molecular techniques) might explain the unique results we 
observed in our study. We did not have access to an indepen-
dent data set for validating our results, but we used the avail-
able data from TCGA-LUAC, and a similar trend to worse 
survival was observed for patients with KRAS-G12C muta-
tions despite the relatively short follow-up time for patient 
outcomes in this cohort at present.
Interestingly, not all lung cancer cells harboring KRAS-
activating mutations are addicted to this oncogene. KRAS-
dependent cells correlated with high KRAS copy number and 
a KRAS dependency gene-expression signature was associ-
ated with a well-differentiated phenotype, whereas KRAS 
independence was associated with EMT and poor differentia-
tion.12 Most KRAS-G12C lung cancer cells have been charac-
terized as KRAS independent and showed an EMT phenotype 
based upon their gene-expression profile. In NSCLC cell lines 
and lung AC, we compared the mutational and transcriptional 
profile among KRAS-G12C and other mutants. No signifi-
cant differences were found in the co-occurrence of muta-
tions involving other relevant cancer genes. Different KRAS 
codon variants did not show a distinctive gene-expression 
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profile and appeared intermixed or merged together with 
EGFR/KRAS wild-type tumors by hierarchical clustering, as 
previously reported for KRAS mutant lung AC.19,31–33 These 
results suggest that KRAS mutant lung AC have an intrinsic 
molecular heterogeneity. By gene-enrichment analysis, EMT 
and angiogenesis-related genes were found overexpressed in 
KRAS-G12C mutant tumors, but further validation in indepen-
dent cohorts is warranted. Strikingly, lung AC tumors harbor-
ing KRAS-G12C mutation had significantly lower KRAS copy 
number and tended to express lower levels of validated genes 
predicting KRAS dependency.
Effective treatments for RAS mutant cancers are an 
unmet clinical need. Although targeting oncogenic RAS 
directly has been challenging due to protein structure issues 
and its high affinity for GTP/GDP, a novel allosteric regula-
tory site has been recently identified on KRAS-G12C and small 
molecules that target this site have been developed.34 In the 
lung cancer adjuvant setting, KRAS mutations were not predic-
tive of benefit from adjuvant chemotherapy.15 In advanced lung 
cancer, KRAS mutations were associated with poor response to 
EGFR tyrosine kinase inhibitors,35 and in a small study, KRAS-
G12C patients had worse PFS when treated with EGFR tyro-
sine kinase inhibitors.36 In addition, advanced NSCLC patients 
with KRAS mutations did not benefit from maintenance with 
erlotinib after receiving four cycles of cisplatin-based chemo-
therapy.37 Similarly, advanced NSCLC patients with KRAS-
G12C and G12V had shorter PFS when treated with targeted 
therapies in the BATTLE trial.10 Several clinical trials using 
small molecule inhibitors to inhibit MEK-ERK and/or PI3K/
AKT pathways are ongoing in patients with KRAS mutations.38 
However, the response to these therapies differs across KRAS 
mutant lung cancer cell lines and tumors and might be limited 
by other factors such as co-occurrence of inactivating muta-
tions in tumor suppressor genes (TP53, STK11, or PTEN),39,40 
or activation of compensatory pathways that will allow can-
cer cells to continue proliferating and evade apoptosis.41,42 
Co-targeting upstream genes or multiple downstream effector 
pathways led to impressive tumor responses in different KRAS 
models.43,44 However, a limitation of this therapeutic strategy 
might be the toxicity associated with the combination of tar-
geted therapies. Alternative therapeutic combinations against 
KRAS mutant cancers have been suggested using synthetic 
lethality approaches.45–47 Further functional studies of specific 
KRAS mutants are necessary to study preferential signaling 
through one or more pathways and guide rational combinations 
of targeted therapies against specific KRAS subtypes.
Even though the prognostic value of KRAS muta-
tions is controversial, we consider that codon variants have 
important biological and therapeutic implications in patients 
with resected lung AC. We hypothesize that tumors harbor-
ing KRAS-G12C mutations might be KRAS independent and 
we believe that distinct KRAS codon variants should be taken 
into account when designing clinical trials for this lung cancer 
population. In conclusion, we found that KRAS-G12C muta-
tion is the most common type of amino acid substitution in 
resected lung ACs and is independently associated with worse 
DFS and OS compared with other KRAS mutants or wild-
type. NSCLC cell lines and lung AC harboring KRAS-G12C 
appeared to have preferentially an EMT phenotype, that is, 
KRAS independent based on the gene-expression profile.
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